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Executive Summary
As a nurse working in chemotherapy infusion, I have a direct role in symptom management. For
patients receiving Taxanes, the most common adverse effect reported by patients is peripheral
neuropathy. According to one meta-analysis, Taxane-induced peripheral neuropathy (TIPN) has
very high incidence ranging from 11 to 87% and severely impairs patients’ quality of life (Jia et
al., 2021). Patients may experience pain, weakness, loss of sensation, decrease in ability to
perform ADLs, increased falls among many other impairments as a result. We understand the
importance of performance status in oncology patients. This can lead to dose reductions or held
treatments depending on the severity of this. With cancer treatment, the prognosis can be
affected by delays in treatment.
As a result of this knowledge, patients implement interventions they have researched online to
prevent chemo-induced peripheral neuropathy. The most common intervention seen is the
application of frozen mittens and socks. Patients implementing this intervention stake claim to
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the efficacy and are persistent in doing it every treatment. I investigated this practice to see if
there was reliable evidence on cryotherapy usage to prevent chemotherapy induced peripheral
neuropathy (CIPN). Upon further investigation, I found use of cryotherapy to the hands and feet
while receiving Taxol-based chemotherapy shows promising results in preventing the
development of peripheral neuropathy. My proposal is to educate patients on this intervention
during their treatment review so they could implement this based off patient preference. This
would be an effective and inexpensive way to combat this debilitating side effect of
chemotherapy and would help sustain quality of life in patients.

Rationale
Taxanes are the first line agents in many different types of cancer and is one of the most common
agents given in the infusion center. With such a high incidence of taxane induced peripheral
neuropathy reported, there should be an intervention available to help ameliorate this. There are
no interventions or education offered at this time to prevent peripheral neuropathy from
treatment. There is however, education being offered on how to reduce side effects such as
nausea, vomiting, diarrhea, stomatitis, skin changes, fatigue, taste changes and any other side
effect you can think of. While working with a new patient recently, she mentioned she had
purchased frozen gloves and socks as recommended by her friend who had gone through the
same treatment and did not develop peripheral neuropathy. She was asking about when she
should apply the gloves during her treatment. She expressed the desire to have been educated on
this at her treatment review as this was the main concern she had, but nothing about this
particular side affect was mentioned. Cryotherapy is being used to reduce the incidence of chemo
induced mucositis, alopecia and cutaneous toxicity at our cancer center. With high levels of
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evidence supporting cryotherapy to prevent CIPN, this intervention should be offered in the
appropriate populations. My proposal is to include this information in the treatment review along
with all the other patient education so patients can implement this.

Literature to Support Project
A search was performed in Pub Med and twelve articles were reviewed over cryotherapy and
chemo induced peripheral neuropathy. Five studies involved participants receiving Taxane
agents using cryotherapy to reduce peripheral neuropathy. There were four randomized
controlled trials and one metanalysis.
Participants in all of the studies except one were undergoing treatment for breast cancer
(Kanbayashi et al. 2020), (Shigematsu et al. 2020), (Akiko Hanai et al., 2018), (Ruddy KJ, LeRademacher J, Lacouture ME, et al 2019) and the other was undergoing treatment for
gynecological cancer (Sato et al. 2016). The neurotoxic chemotherapies received by the subjects
were Taxol, Albumin bound paclitaxel and Taxotere. Cryotherapy was used in all studies by way
of using either a frozen gloves or mittens and frozen socks applied to the hands and feet starting
15-30 minutes prior to starting chemotherapy infusion and left on for up to 60 minutes after
completion. The Common Terminology Criteria for Adverse Events (CTCAE) was used in four
of the five articles to test the outcome (Sato et al. 2016) (Kanbayashi et al. 2020) (Shigematsu et
al. 2020), along with other methods including: Patient Neurotoxicity Questionnaire (PNQ),
Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-T),Thermography, Nam
equivalence test (Kanbayashi et al. 2020) FACT-NTX, PNQ,CTCAE,FACT-Taxane
(Shigematsu et al. 2020), monofilament test, thermal stimulator, C 128-Hz tuning fork, grooved
pegboard test, patient-reported questionnaire on neuropathy and activities of daily living (Akiko
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Hanai et al., 2018), European Organisation for Research and Treatment of Cancer (EORTC
QLQ‐CIPN2), (Ruddy KJ, Le-Rademacher J, Lacouture ME, et al 2019). Four out of five studies
demonstrated statistical significance to the benefit of cryotherapy in reducing the severity of
chemo induced peripheral neuropathy.

Project Stakeholders
In order to have sustainability in a change, the interest of the practice stakeholders is critical. It is
important to align the vision of the practice with the change proposed. In the case of my
benchmark project of using cryotherapy to prevent peripheral neuropathy, the stakeholders will
include the doctors, nurses and most importantly the patients. The stakeholders in this project
would be the doctors prescribing treatments and the nurse practitioners teaching treatment
reviews who would educate patients on this intervention. The practice administrator and the
nursing manager both of whom serve as a gatekeeper for the practice and clinical areas would
grant permission for the benchmark project. The nurse assistant manager is a change champion
who would support efforts to implement by gaining nursing staff buy in and development of
teaching materials for patients. The practice administrator would obtain permission from the
doctors and support me by allowing pharmacy ice packs to be used by patients. Lastly patients
receiving the intervention would serve as a stakeholder by proving feedback on the efficacy of
this intervention and on quality improvement.
Proposed Outcomes
The outcome to be measured in this benchmark is a reduction in the development of Taxane
induced peripheral neuropathy as a result of having used cryotherapy during treatment. With data
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showing significant reduction in the development of peripheral neuropathy with use of
cryotherapy, this could be a beneficial intervention our practice could educate patients about to
help reduce adverse effects from chemo treatments.
Evaluation Design
Evaluating the outcome of my benchmark project will involve assessing the intervention itself
and the response from nursing staff. To evaluate the staff’s response to the ease of
implementation, the project change lead could attend the chemo nurse meetings on Mondays and
ask for feedback. This multisource feedback will determine understanding of where things stand
and give a clear direction of travel in terms of improving behaviors, attitudes and skills.
To evaluate the effects of cryotherapy in preventing chemotherapy induced peripheral
neuropathy the nursing staff in the chemo dept would assess the level of peripheral neuropathy
when patient’s come for weekly treatments and document it in the patient’s EMR. The PNQ
(patient neurotoxicity questionnaire) could be given to patients to fill out at baseline, 6 weeks
which would be halfway through a 12-week regimen and at 12 weeks. When patient’s come back
for a scan after completion of chemo the level of peripheral neuropathy could be checked again.

Timetable/Flowchart

This change project will be held within Tx Oncology clinic and infusion room.
Data needed before initiating the project include the incidence rates of peripheral neuropathy,
chemotherapy dose reductions due to peripheral neuropathy, and an estimated loss of billable
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units due to dose reductions and held treatments from peripheral neuropathy. This data will help
in gaining stakeholder buy in. An assessment of the current educational materials distributed
during treatment reviews will be done and new education on the use of cryotherapy can be
added. The next step is to present all of this information to the stakeholders with the practice
administrator’s support and gain permission to move forward. After gaining permission from the
doctors to move forward, an evaluation of the infrastructure is needed and teams could be
formed. The teams will consist of a change champion which will be myself for the nursing staff
and the assistant manager for the nurse practitioners. We will assess for barriers to change from
gaining feedback from the nurse practitioners and nurses during the Monday nurse meetings.
Next a clinical tool will be developed to help with implementation of the project and decision
making. After the development of a clinical tool, a pilot of the change can be launched. Nurse
practitioners can begin educating patients on cryotherapy during the treatment review process
and patients who decide to implement this intervention can begin doing so during infusion. After
having done a pilot of the intervention for two weeks, dissemination of the process can be gained
through feedback from infusion nurses, patients and nurse practitioners. Changes to the process
can be made based on this feed-back. Further implementation can be planned and after 12 weeks
the benefits can be measured through patient feedback and surveys and the process can be
refined on an on-ongoing basis.
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Evaluate Current
Practice, Analyze
Qality Data- 2
weeks

Disseminate
Evidence/Educate
Staff-2 weeks

Implement Practice
Change-2 weeks

Introduce Change
to Stakeholders- 1
week

Conduct Pilot-2
weeks

Measure
Outcomes- after 12
weeks

Evaluate
Infrastructure and
Form Teams-1 week

Assess for Barriers
to Change-1 week

Refine Processongoing (Melnyk &
Fineout-Overholt
2019, p.283).

Data Collection Methods
In order to collect data to determine the success of the benchmark the The PNQ (patient
neurotoxicity questionnaire) could be given to patients to fill out at baseline, 6 weeks which
would be halfway through a 12-week regimen and at 12 weeks. The PNQ represents a simple
self-administered assessment tool created by BioNumerik Pharmaceuticals, Inc. containing data
from the FDA. It involves specific questions that aim to draw quantifiable and important
diagnostic information directly from CIPN patients that regard both the severity and incidence of
subjective CIPN symptoms (Tsoleridis et al., 2021). This tool is a reliable data collection method
and was used in most of the randomized controlled trials which studied the effects of
cryotherapy. Other data collection methods will be obtaining direct feedback from nursing staff
at huddles and from patients at their treatments weekly which can be documented in the patients
EMR.
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Discussion of Evaluation
This benchmark has not been evaluated. The assistant nurse manager has acknowledged this to
be a great intervention worth implementing and is pulling education materials together to begin
the process of adding this to the treatment reviews. Patients who I have discussed this with are in
agreement this would have been something they would be interested in doing had they been
aware prior to starting treatment. Nurses in the infusion department agree to supporting this
intervention.
Cost/Benefits
Since this is a benchmark project, I did not have access to patients’ personal financial
information however, the amount of money lost from treatments being held or dose reduced
would be determined by assessing the average amount of money insurance pays for each cycle of
Taxol. When a treatment is held due to the development of peripheral neuropathy there are no
charges for that cycle. This would include admix charges as well as pre-medications in addition
to the actual chemo Taxol. When a dose is reduced, less vials of medication are charged out
which is a loss of billable units. I would look at how many treatments were held or dose reduced
for a year due to peripheral neuropathy and multiply this by the average amount of money
insurance pays for the Taxol infusion to determine the amount of money lost annually. The cost
of educating a patient on the intervention of cryotherapy is free. The cost of providing ice packs
from the pharmacy is also free and we currently already do this for patients receiving Doxil
infusions so this would be no different. Patients can keep these ice packs and re-use or purchase
frozen gloves on their own. This simple solution could prevent the development of peripheral
neuropathy for patients and save the practice thousands of dollars from treatments being held or
dose reduced.
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Conclusion/Recommendations
In conclusion, the use of cryotherapy to the hands and feet while receiving taxol-based
chemotherapy shows promising results in preventing the development of peripheral neuropathy.
This intervention would be an effective and inexpensive way to combat this debilitating side
effect of chemotherapy and would help sustain quality of life in patients. I recommend our
practice begin to educate patients on this intervention and support patients who choose to
implement it by providing ice packs from the pharmacy if they need them and do not already
have their own. This could be an easy and inexpensive method to provide the best evidenced
based care to our patients.

References

Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa,
Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama,
Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki
Nakagawa, Satoshi Imai, Yoko Hamabe, and Masakazu Toi. 2018. “Effects of
Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced
Neuropathy: Prospective Self-Controlled Trial.” JNCI: Journal of the National
Cancer Institute 110(2):1–148.
Jia, J., Guo, Y., Sundar, R., Bandla, A., & Hao, Z. (2021). Cryotherapy for Prevention of
Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. Frontiers in Oncology,
11, 781812. https://doi.org/10.3389/fonc.2021.781812

12

Kanbayashi, Yuko, Koichi Sakaguchi, Takeshi Ishikawa, Yoshimi Ouchi, Katsuhiko
Nakatsukasa, Yusuke Tabuchi, Fuminao Kanehisa, Minako Hiramatsu, Ryo
Takagi, Isao Yokota, Norito Katoh, and Tetsuya Taguchi. 2020. “Comparison of
the Efficacy of Cryotherapy and Compression Therapy for Preventing
Nanoparticle Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy: A
Prospective Self-Controlled Trial.” The Breast 49:219–24.
Melnyk, B. M., & Fineout-Overholt, E. (2019). Evidence-based practice in nursing &
healthcare: A guide to best practice. Philadelphia: Wolters Kluwer.
Ruddy KJ, Le-Rademacher J, Lacouture ME, et al. Randomized controlled trial of cryotherapy to
prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU
trial. Breast. 2019;48:89-97. doi:10.1016/j.breast.2019.09.011
Rosenbaek, F., Holm, H. S., Hjelmborg, J. v. B., Ewertz, M., & Jensen, J. D. (2020). Effect of
cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer.
Supportive Care in Cancer, 28(8), 3763–3769. https://doi.org/10.1007/s00520019-05196-z
Sato, Junya, Megumi Mori, Satoru Nihei, Masumi Kumagai, Satoshi Takeuchi, Masahiro
Kashiwaba, and Kenzo Kudo. 2016. “The Effectiveness of Regional Cooling for
Paclitaxel-Induced Peripheral Neuropathy.” Journal of Pharmaceutical Health
Care and Sciences 2(1):33
Shigematsu, Hideo, Taizo Hirata, Mai Nishina, Daisuke Yasui, and Shinji Ozaki. 2020.
“Cryotherapy for the Prevention of Weekly Paclitaxel-Induced Peripheral
Adverse Events in Breast Cancer Patients.” Supportive Care in Cancer.

13

Tsoleridis, T., Chloropoulou, P., Tsaroucha, A., Vadalouca, A., Siafaka, I., & Vogiatzaki, T.
(2021). Validation of the Patient Neurotoxicity Questionnaire for Patients
Suffering From Chemotherapy-Induced Peripheral Neuropathy in Greek. Cureus,
13(4). https://doi.org/10.7759/cureus.14324

Appendix

14

15

